For

addi

tion

al in

form

atio

n or

to r

egis

ter

onlin

e, c

onta

ct:

htt

ps:

//cc

ehs.

up

mc.

com

F e b r u a r y 1 3 – 1 5 , 2 0 1 6

Eleventh International Symposium on

Regional Cancer TherapiesSheraton Wild Horse Pass Resort & Spa

Chandler, Arizona

Sponsored by

David C. Koch

Regional Cancer Therapy Center

and

University of Pittsburgh School of Medicine

Center for Continuing Education

in the Health Sciences

and

UPMC Cancer Centers

In Collaboration with

The University of Maryland

Marlene and Stewart Greenebaum

Cancer Center

and

The Medical College of Wisconsin

Cancer Center

Course Co-Directors

H. Richard Alexander, MD

Professor of Surgery

University of Maryland Medical Center

Baltimore, Maryland

David L. Bartlett, MD

Professor of Surgery

University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania

Robert P. Edwards, MD

Professor, Obstetrics and Gynecology and

Reproductive Services

University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS

Stuart D. Wilson Chair in Surgical Oncology

Chief, Division of Surgical Oncology

Associate Professor of Surgery

Medical College of Wisconsin

Milwaukee, WisconsinDavid

C. K

och

Regi

onal

Canc

er T

hera

py C

ente

r

UPM

C Ca

ncer

Pav

ilion,

Sui

te 4

13

5150

Cen

tre A

venu

e

Pitts

burg

h, P

A 15

232

Nonp

rofit

Org

.U.

S. P

osta

gePA

IDPi

ttsbu

rgh,

PA

Perm

it No

. 383

4

Ele

ven

th I

nte

rnat

ion

al S

ympo

siu

m o

n

Reg

ion

al C

ance

r T

hera

pies

Sher

aton

Wil

d H

orse

Pas

s R

esor

t &

Spa

– C

han

dler

, Ari

zon

a

Fe

br

ua

ry

13

–1

5,

20

16

~ 2 ~ ~ 3 ~

Intent and Overview

This course is designed to cover the most recent advances in cancer therapy that are

primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian

and thoracic. Upon completion of the activity, learners from several disciplines should

be able to discuss the latest regional therapies in surgical oncology.

Who Should Attend

This course is designed for physicians and nurses practicing in the areas of Medical,

Surgical, Thoracic and Gynecologic Oncology and Gastroenterology.

Continuing Education Credit

The University of Pittsburgh School of Medicine is accredited by the Accreditation

Council for Continuing Medical Education to provide continuing medical education

for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a

maximum of 20.75 AMA PRA Category 1 Credits™. Physicians should claim only the

credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 2.0 continuing education units (CEU’s)

which are equal to 20.7 contact hours.

Special Needs

Participation by all individuals is encouraged. Advance notification of any special needs

will help us provide better service. Please notify us of your needs at least two weeks in

advance of the program by calling Maureen Hewko at (412) 623-5993.

We Gratefully Acknowledge Support from:

Magee-Womens Research Institute & Foundation

Schedule – Saturday, February 13, 2016

6:30 am Registration and Breakfast

6:45 am Welcome

Moderators: Steven Ahrendt, MD and Guillermo Flores Ayala, MD

7:00 am The Comprehensive Complication Index: A New Measure

of the Burden of Complications after HIPEC

Sinziana Dumitra, MD, et. al.

7:15 am Re-admissions for Delayed Complications after CRS and HIPEC

Vassiliki Manou, MD, et. al.

7:30 am Goal-Directed Fluid Management Improves Morbidity Associated with

Extended Cytoreduction and HIPEC

Laura Lambert, MD, et. al.

7:45 am Repeat CRS and HIPEC for the Treatment of Recurrent Peritoneal Surface

Malignancy: Is it Worthwhile?

Ramy Fouad, MD, et. al.

8:00 am Delayed Gastric Emptying following CRS and HIPEC

Lola Chabtini, MD, et. al.

8:15 am Acute Kidney Injury in Patients Undergoing CRS plus HIPEC

George Salti, MD, et. al.

8:30 am Impact of Previous Gynecologic Surgical Procedures on Short Term and

Oncological Outcomes in Patients Treated with CRS and HIPEC

Marcello Guaglio, MD, et. al.

8:45 am Is Diverting Ostomy Needed in High-Risk Anastomosis During

Cytoreductive Surgery and HIPEC?

Matthew Whealon, MD, et. al.

9:00 am Impact of Chemotherapy Regimen on Post-Operative Complications

After CRS and HIPEC

Juan Camilo Correa, MD, et. al.

9:15 am Debate: Repeat CRS/HIPEC for Patients Who Recur within Two Years?

Moderator: John Kane III, MD

YES — Kiran Turaga, MD NO — Konstantinos Votanopoulos, MD

9:45 am Break

~ 4 ~ ~ 5 ~

Moderators: T. Clark Gamblin, MD, MS and James Cusack, MD

10:00 am Does Fellowship Training Overcome the Learning Curve in Cytoreductive

Surgery and Heated Intraperitoneal Chemoperfusion

Cameron Schlegel, MD, et. al.

10:15 am Defining Selection Criteria for Patients with Advanced Peritoneal Carcinomatosis of Colorectal Origin

C. Komen Brown, MD, et. al.

10:30 am Impact of Body Mass Index (BMI) on Morbidity and Mortality in

Cytoreductive Surgery (CRS) with Intraperitoneal Chemotherapy (IPC)

Giorgos Karakousis, MD, et. al.

10:45 am Hepatic Artery Infusion for Recurrent or Chemo Resistant

Hepatic Malignancy

Harold Wanebo, MD, et. al.

11:00 am Novel Mouse Models of Hepatic Artery Infusion (HAI)

Minhyung Kim, MD, et. al.

11:15 am Overall Survival after Ablation for Small Size Hepatocellular Carcinoma

at Academic Cancer Centers vs. Community Cancer Centers

Nicholas Berger, MD, et. al.

11:30 am Ablation for Small HCC Lesions: Is Chemotherapy Necessary?

Nicholas Berger, MD, et. al.

11:45 am Liver Resection Following Selective Internal Radiation Treatment with

Yttrium-90: A Bi-Institutional Analysis

G. Paul Wright, MD, et. al.

Noon GUEST LECTURER

Hepatic Artery Infusional Chemotherapy for Primary and

Metastatic Cancer

Michael D’Angelica, MD, FACS

12:30 pm Break for Lunch

12:45 pm CASE PRESENTATION AND DISCUSSION

Discussants: H. Richard Alexander, MD and Nathan Bahary, MD

Immunotherapy for Peritoneal Carcinomatosis

Nathan Bahary, MD

Hepatoid Carcinoma of the Ovary with Peritoneal Metastases Treated

with Cytoreductive Surgery and HIPEC

Samer Naffouje, MD, et. al.

Unusual Presentation of Pseudomyxoma Peritonei

Amy Schulze, MD, et. al.

Intrauterine Metastases of Appendiceal Tumors Impact Cytoreduction

Jessica Cintolo-Gonzalez, MD, et. al.

Cytoreductive Surgery and HIPEC for Sarcomatosis from Uterine

Adenosarcoma

Michael O’Leary, MD, et. al.

Peritoneal Recurrent Fibrolamellar Hepatocullar Carcinoma Treated

with CRS and HIPEC

David Brown, MD, et. al.

1:45 pm Saturday Session Adjournment

6:00 pm Poster Sessions

7:00 pm MEET THE PROFESSOR RECEPTION

Presentation of Gabriella Graham Patient Advocate Award

by Laura Lambert, MD

Schedule – Sunday, February 14, 2016 6:30 am Registration and Breakfast 6:45 am Welcome

Moderators: Jason Foster, MD and Matthew Holtzman, MD

7:00 am Recurrence of Malignant Peritoneal Mesothelioma:

Insights Based on Standardized Second Look Procedures

Michael Kluger, MD, et. al.

~ 6 ~ ~ 7 ~

7:15 am Peritoneal Surface Oncology Group International Registry on Peritoneal Mesothelioma

Marcello Deraco, MD, et. al. 7:30 am Outcomes of Well-Differentiated Papillary Peritoneal Mesothelioma Garrett Nash, MD, et. al. 7:45 am Nomogram to Predict Overall Survival in Diffuse Malignant Peritoneal

Mesothelioma: A Peritoneal Surface Oncology Group International (PSOGI) Multicenter Study

Shigeki Kusamura, MD, et. al. 8:00 am Long-term Combined Intraperitoneal and Systemic Chemotherapy for

Patients with Malignant Mesothelioma Results in Improved Survival Paul Sugarbaker, MD, et. al. 8:15 am Dual Cavity Malignant Mesothelioma: Presentation and Survival Yaakov Bressler, MD, et. al. 8:30 am Analysis of Outcomes in Young Patients (≤ 50 y) with Malignant

Peritoneal Mesothelioma Treated with Cytoreductive Surgery and HIPEC Julie Terhune, MD, et. al.

8:45 am Predicting Risk of Peritoneal Recurrence in Stage II Colon Cancer: Secondary Analysis of CALGB9581 Trial

Rahul Rajeev, MD, et. al. 9:00 am Multimodality Therapy for Peritoneal Metastases from Epithelial

Ovarian Cancer Deepa Magge, MD, et. al.

9:15 am GUEST LECTURER

Scientific Basis for CRS and HIPEC in the Treatment of Peritoneal Metastases: A Historical Perspective

Paul Sugarbaker, MD

9:45 am Break/Exhibitors/Posters Moderators: Robert Edwards, MD and Marcello Deraco, MD

10:00 am Perioperative Systemic Chemotherapy for Peritoneal Mucinous

Appendiceal Carcinomas Treated with Cytoreductive Surgery and HIPEC

John Spiliotis, MD, et. al.

10:15 am Multi-institution Review of the Role of Cytoreductive Surgery

and Heated Intraperitoneal Chemotherapy in Metastatic Gastric

Adenocarcinoma in the U.S.

Laura Enomoto, MD, et. al.

10:30 am Management of Peritoneal Carcinomatosis of a Colonic Origin: Role of

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy:

A Single Institution’s Experience over Two Decades

Chukwuemeka Ihemelandu, MD, et. al.

10:45 am Cytoreductive Surgery and HIPEC: Can We Improve Survival with Less

Postoperative Complications?

Mecker Moller, MD, et. al.

11:00 am Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases

Combined with Curative Surgery for Hematogenous Metastases:

Analysis of Early and Long-Term Outcomes

Dario Baratti, MD, et. al.

11:15 am Peritonectomy Procedures Combined with HIPEC in Advanced Ovarian

Cancer Retrospective Italian National Multicenter Observational Study:

Update of 503 Cases

Paolo Sammartino, MD, et. al.

11:30 am Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors

with Peritoneal Dissemination After HIPEC

Joel Baumgartner, MD, et. al.

11:45 am Cytoreductive Surgery and HIPEC in the Management of Uterine

Sarcoma (US) with Peritoneal Dissemination (PD)

Armando Sardi, MD, et. al.

Noon GUEST LECTURER

New Advances in the Immunotherapy of Ovarian Cancer

Adekunle Odunsi, MD, PhD

12:30 pm Lunch

~ 8 ~ ~ 9 ~

1:00 pm PROPOSED AND ONGOING CLINICAL TRIALS

Discussants: Charles Staley, MD and Jesus Esquivel, MD

Assessment of Pre-Operative PCI Scoring with Integrated PET-DWI-MRI in Patients with Peritoneal Carcinomatosis: A Feasibility Pilot Study in Development

Daniel Labow, MD, et. al.

A Minimally Invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy

Kaitlyn Kelly, MD, et. al.

A Phase I Clinical Trial of Bi-Directional Chemotherapy for Unresectable Appendiceal or Colon Cancer

Bradley Switzer, MD, et. al.

A Phase II Study to Evaluate Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma with Peritoneal Carcinomatosis

Joel Baumgartner, MD, et. al.

The Role of Second-Look Laparoscopy in Patients at Risk of Recurrent Peritoneal Carcinomatosis

Yahel Agmon, MD, et. al.

Phase I/II Trial Evaluating aDCI Vaccines Combined with Tumor-selective Chemokine Modulation as Adjuvant Therapy after Surgical Resection of Peritoneal Surface Malignancies

Mark Girgis, MD

Update on ICARUS: A Randomized Trial of Intraperitoneal Chemotherapy After CRS for Appendiceal or Colorectal Carcinoma

Garrett Nash, MD

Prospective Randomized Trial Comparing Mitomycin and Oxaliplatinum in the Perfusate of Patients Undergoing HIPEC for Cancer of Appendix

Edward Levine, MD

2:00 pm Sunday Session Adjournment 6:00 pm Poster Viewing 7:00 pm ASPSM Meeting Schedule – Monday, February 15, 2016 6:30 am Registration and Breakfast 6:45 am Welcome

Moderators: Jonathan Zager, MD and Douglas Tyler, MD

7:00 am Pulmonary Suffusion for Oligometastatic Malignancies Todd Demmy, MD, et. al. 7:15 am BrachyVAC Treatment of Superficial Malignancies: Results of a

Consecutive Case Series Mark Goodman, MD, et. al. 7:30 am Clinical Response and Regional Toxicity Following Isolated Limb Infusion

Compared to Isolated Limb Perfusion for In-Transit Melanoma Metastases Lesly Dossett, MD, et. al. 7:45 am Electrochemotherapy in Locally Advanced Melanoma and Non-

Melanoma Skin Cancer: Experience from a Single Institution Alessandro Testori, MD, et. al. 8:00 am Inflammation-based Prognostic Scores; Utility in Prognostication and

Patient Selection for Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with PC of a Colonic Origin

Chukwumeka Ihemelandu, MD, et. al. 8:15 am Aminolevulinic acid (ALA) is a Promising Compound for Detection of

Small Peritoneal Metastases: ALA Guided Cytoreductive Surgery Yutaka Yonemura, MD, et. al. 8:30 am A Comparison of Appendectomy Only vs. Cytoreductive Surgery and

HIPEC in 59 Patients with Early Stage Mucinous Appendiceal Neoplasms Jesus Esquivel, MD 8:45 am A Comprehensive Evaluation of Barriers to Referral of Patients for

Cytoreductive/HIPEC Valerie Francescutti, MD, et. al. 9:00 am A Snapshot of CS/HIPEC Perioperative Care Practice Patterns Around

the World: On the Pathway to Success or Opportunity for Improvement Allison Maciver, MD, et. al. 9:15 am Prognostic Factors and Significance of Gastrointestinal Leak

after Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC)

Konstantinos Chouliaras, MD, et. al. 9:30 am GUEST LECTURER

The Genetics of Peritoneal Surface Malignancies: Insights and Opportunities

Andrew Lowy, MD

10:00 am Break/Exhibitors/Posters

~ 10 ~ ~ 11 ~

Moderators: James Pingpank, MD and Brian Loggie, MD

10:15 am Multimodality Approach to Peritoneal Metastases: 1312 Patients Treated by a Multi-Disciplinary Team

Haroon Choudry, MD, et. al. 10:30 am Molecular Profiling: Prognostic Biomarkers in Patients Presenting with

Peritoneal Carcinomatosis of the Appendix and Colon Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Chukwuemeka Ihemelanda, MD, et. al. 10:45 am Single-Port Access for Pressurized Intra-Peritoneal Aerosol

Chemotherapy (PIPAC): Feasibility and Safety Michele DeSimone, MD, et. al. 11:00 am MDM-2 Overexpression in Human Stem-like and Mature Colon

Cancer Cells as a Target for Anti-Cancer Therapy: Steps Toward a Translational Model

Mohammad Shaikh, MD, et. al. 11:15 am The Use of a pH-activated Indocyanine Green-Encoded Nanosensor

(PINS) for Detection of Peritoneal Disease Glen Balch, MD, et. al. 11:30 am Evaluation of Glycoprotein Expression Profiles in Peritoneal Metastases Asish Patel, MD, et. al. 11:45 am Exploration of Mutations in GI Cancers with Peritoneal Metastasis Asish Patel, MD, et. al. Noon Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System

for Cytoreductive Surgery Carlos HF Chan, MD, et. al. 12:15 pm Molecular Profiling of Appendix-Derived Pseudomyoxoma Peritonei (PMP) Elizabeth Gleeson, MD, et. al. 12:30 pm Analysis of Twenty Years of Reporting on Hyperthermic Intraperitoneal

Chemotherapy for Colorectal Cancers: Proposal for Standardized Reporting Samer Naffouje, MD, et. al. 12:45 pm Break for Lunch

12:55 pm Announcement and Presentation of Poster Award Winners 1:00 pm Conference Adjournment

Poster Presentations

1. The Effect of Perfusate Buffering on Toxicity and Response in Isolated Hepatic

Perfusion for Uveal Melanoma Metastases – Ilan Ben-Shabat, MD, et. al.

2. The Potential Impact of Host Murine Granulocytes on Growth of Human

Appendiceal Cancer – Laura Lambert, MD, et. al.

3. Expression of Adhesion Molecules in Peritoneal Carcinomatosis from Colon

Cancer: Identification of New Prognostic Factors – Simone Sibio, MD, et. al.

4. A Novel Approach to Diaphragm Resection in Cytoreductive Surgery – Cameron

Schlegel, MD, et. al.

5. A Phase II Randomized Study: Outcomes after Cytoreductive Surgery (CRS) with or

without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed

by Adjuvant Chemotherapy as Initial Treatment – Armando Sardi, MD, et. al.

6. BRAF Status as a Predictive Factor for Response in Isolated Limb Perfusion – Ilan

Ben-Shabat, MD, et. al.

7. Intensive Care Unit Hospitalization after Cytoreductive Surgery and Hyperthermic

Intraperitoneal Chemotherapy (HIPEC) – John Spiliotis, MD, et. al.

8. Creating a Primary Regional Referral Center for Cytoreductive Surgery and Hyper­

thermic Intraperitoneal Chemotherapy (CRS/HIPEC) – Ea-sle Chang, MD, et. al.

9. CEA Level Predicts Oncologic Outcomes Following Surgical Resection of Colorectal

Peritoneal Metastases – G. Paul Wright, MD, et. al.

10. Does Upfront Therapy with Cytoreductive Surgery and HIPEC Confer a Survival

Benefit in Patients with Synchronous Gastric Peritoneal Carcinomatosis when

Compared with Patients with Metachronous Gastric Peritoneal Carcinomatosis. –

Nikolaos Kopanakis, MD, et. al.

11. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Provides a

Survival Benefit in Unresectable Peritoneal Carcinomatosis – Mecker Moller, MD, et. al.

12. Perioperative Hyperglycemia in Patients Undergoing Cytoreductive Surgery and

HIPEC – Julie Campbell, MD, et. al.

13. Water Lavage during Cytoreductive Surgery with Hyperthermic Intraperitoneal

Chemotherapy (CRS – HIPEC) – Emmanuel Gabriel, MD, et. al.

~ 12 ~ ~ 13 ~

14. An Investigation of Factors Necessitating Abortion of Cytoreduction and HIPEC in a

Newly Established Center for Peritoneal Malignancy – Whitney Guerrero, MD, et. al.

15. Impact of KRAS/BRAF Mutations in Patients with Colorectal Peritoneal

Metastases ­ G. Paul Wright, MD, et. al.

16. Does Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Lead

to Worse Quality of Life? – Gregory Tiesi, MD, et. al.

17. Predictors of Palliative Care Consultation in Patients Undergoing Hyperthermic

Intraperitoneal Chemotherapy (HIPEC) – Rachel Morris, MD, et. al.

18. Trends in Utilization of CRS and HIPEC for Peritoneal Malignancies –

Kazi Ullah, MD, et. al.

19. Clinicopathological Features of Appendix Mucocele: Are We Too Aggressive? –

William Morano, MD, et. al.

20. Let’s Agree to Agree: Unification of Practice Among High­Volume CS/HIPEC

Surgeons in the United States – Eisar Al-Sukhni, MD, et. al.

21. Regional Therapy for Isolated Peritoneal Metastases from Small Bowel

and Upper Gastrointestinal Malignancies – Deepa Magge, MD, et. al.

22. Same Day Extubation After Cytoreductive Surgery and HIPEC –

Hatem Halabi, MD, et. al.

Course Co-Directors

H. Richard Alexander, MDProfessor of Surgery

University of Maryland School of Medicine

Baltimore, MD

David L. Bartlett, MDProfessor of Surgery

University of Pittsburgh School of Medicine

Robert P. Edwards, MDProfessor, Obstetrics, Gynecology and

Reproductive Sciences

University of Pittsburgh School of Medicine

T. Clark Gamblin, MD, MSStuart D. Wilson Chair in Surgical Oncology

Chief, Division of Surgical Oncology

Associate Professor of Surgery

Medical College of Wisconsin

Milwaukee, WI

Guest Faculty

Michael D’Angelica, MD, FACSEnid A. Haupt Chair in Surgery, Memorial

Sloan Kettering Cancer Center

Attending Surgeon, Hepatopancreatobiliary

Service, Memorial Sloan Kettering

Cancer Center

Program Director, Complex Surgical

Oncology and HPB Fellowship

Professor of Surgery, Cornell University,

Weill Medical College

New York, NY

Andrew Lowy, MDProfessor of Surgery

UC San Diego Medical Center

School of Medicine

La Jolla, CA

Adekunle Odunsi, MD, PhDCancer Center Deputy Director

The M. Steven Piver Professor and Chair

Department of Gynecologic Oncology

Executive Director, Center for

Immunotherapy

Roswell Park Cancer Institute

New York, NY

Paul H. Sugarbaker, MDDirector, Program in Peritoneal Surface

Malignancy

Washington Hospital Centre

Washington, DC

Invited Faculty

Steven Ahrendt, MDAssociate Professor of Surgery

University of Pittsburgh School of Medicine

Guillermo Flores Ayala, MD Instituto Jaliscience de Cancerologia

Guadalajara, Mexico

Nathan Bahary, MDAssociate Professor of Medicine

University of Pittsburgh School of Medicine

Glen Balch, MDAssistant Professor of Surgery

University of Texas

Dallas, TX

Joel Baumgartner, MDUCSD Moores Cancer Center

La Jolla, CA

C. Komen Brown, MDCancer Treatment Centers of America

Zion, IL

Haroon Choudry, MDAssistant Professor of Surgery

University of Pittsburgh School of Medicine

~ 14 ~ ~ 15 ~

James Cusack, MDAssociate Professor of Surgery

Harvard Medical School

Boston, MA

Marcello Deraco, MDSurgical Oncologist

Foundazione IRCCS Instituto

Nazionale dei Tumori

Milano, Italy

Jesus Esquivel, MDMedical Director, International

Oncology Initiatives

CTCA

Philadelphia, PA

Jason Foster, MDAssociate Professor of Surgery

Nebraska Medical Center

Omaha, NE

Matthew Holtzman, MDAssociate Professor of Surgery

University of Pittsburgh School of Medicine

John Kane III, MDAssociate Professor of Oncology

Roswell Park Cancer Institute

Associate Professor of Surgery

University of Buffalo

Buffalo, NY

Daniel Labow, MDThe Mount Sinai Medical Center

New York, NY

Laura Lambert, MDUniversity of Massachusetts

Medical School

Worcester, MA

Edward Levine, MDProfessor of Surgery

Wake Forest University

Winston­Salem, NC

Brian Loggie, MDProfessor of Surgery

Creighton University Medical Center

Omaha, NE

Garrett Nash, MDMemorial Sloan Kettering Cancer Center

New York, NY

James Pingpank, MDAssociate Professor of Surgery

University of Pittsburgh School of Medicine

Charles Staley, MDProfessor of Surgery

Emory University

Atlanta, GA

Kiran Turaga, MDAssistant Professor of Surgery

Medical College of Wisconsin

Milwaukee, WI

Douglas S. Tyler, MDProfessor of Surgery

Duke University

Durham, NC

Konstantinos Votanopoulos, MDAssociate Professor of Surgery

Wake Forest University

Winston­Salem, NC

Jonathan Zager, MDAssociate Professor of Surgery

Moffitt Cancer Center

Tampa, FL

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise.

The University of Pittsburgh is an affirmative action, equal opportunity institution.

Abstract/Poster Presenters

Yahel Agmon, MDThe Mount Sinai Medical Center

New York, NY

Eisar Al-Sukhni, MDRoswell Park Cancer Institute

Buffalo, NY

Dario Baratti, MDInstituto Nazionale Tumori

Milano, Italy

Ilan Ben-Shabat, MDSahlgrenska University Hospital

Gothenburg, Sweden

Nicholas Berger, MDMedical College of Wisconsin

Milwaukee, WI

Yaakov Bressler, MDColumbia University Medical Center

New York, NY

David Brown, MDSwedish Cancer Institutte

Seattle, WA

Julie Campbell, MDPenn State Hershey College of Medicine

Hershey, PA

Lola Chabtini, MDIndiana University Department of Surgery

Indianapolis, IN

Carlos HF Chan, MDMassachusetts General Hospital

Boston, MA

Ea-sle Chang, MDSt. Louis University Hospital

St. Louis, MO

Konstantinos Chouliaras, MDWake Forest Baptist Health

Winston­Salem, NC

Jessica Cintolo-Gonzalez, MDMassachusetts General Hospital

Boston, MA

Juan Camilo Correa, MDUniversity of Toronto

Toronto, Canada

Todd Demmy, MDRutgers Cancer Institute of New Jersey

New Brunswick, NJ

Michele DeSimone, MDFoundazione IRCCS InstitutoNazionale

dei Tumori

Milano, Italy

Lesly Dossett, MDH. Lee Moffitt Cancer Center and

Research Institute

Tampa, FL

Sinziana Dumitra, MDCity of Hope

Duarte, CA

Laura Enomoto, MDPenn State Hershey Medical Center

Hershey, PA

Ramy Fouad, MDIcahn School of Medicine at

Mount Sinai

New York, NY

Valerie Francescutti, MDRoswell Park Cancer Institute

Buffalo, NY

Emmanuel Gabriel, MDRoswell Park Cancer Institute

Buffalo, NY

Mark Girgis, MDUniversity of Pittsburgh Medical Center

Pittsburgh, PA

~ 16 ~ ~ 17 ~

Elizabeth Gleeson, MDDrexel University College of Medicine

Philadelphia, PA

Mark Goodman, MDUniversity of Pittsburgh Medical Center

Pittsburgh, PA

Marcello Guaglio, MDFoundazione IRCCS Instituto

Nazionale dei Tumori

Milano, Italy

Whitney Guerrero, MDUniversity of Tennessee Health Center

Memphis, TN

Hatem Halabi, MDCancer Treatment Centers of America

Zion, IL

Chukwuemeka Ihemelandu, MDMedStar Washington Hospital Center

Washington, DC

Giorgos Karakousis, MDHospital of the University of Pennsylvania

Philadelphia, PA

Kaitlyn Kelly, MDUniversity of California, San Diego

La Jolla, CA

Minhyung Kim, MDRoswell Park Cancer Institute

Buffalo, NY

Michael Kluger, MDColumbia College of Physicians and

Surgeons

New York, NY

Nikolaos Kopanakis, MDMetaxa Cancer Center

Piraeus, Greece

Shigeki Kusamura, MDMilan Tumor Institute

Milano, Italy

Allison Maciver, MDRoswell Park Cancer Institute

Buffalo, NY

Deepa Magge, MDUniversity of Pittsburgh Medical Center

Pittsburgh, PA

Vasiliki Manou, MDMetaxa Cancer Hospital

Piraeus, Greece

Mecker Moller, MDUniversity of Miani Miller School of

Medicine

Miami, FL

William Morano, MDDrexel University College of Medicine

Philadelphia, PA

Rachel Morris, MDMedical College of Wisconsin

Milwaukee, WI

Samer Naffouje, MDUniversity of Illinois at Chicago

Chicago, IL

Michael O’Leary, MDCity of Hope National Medical Center

Duarte, CA

Asish Patel, MDUniversity of Nebraska Medical Center

Omaha, NE

Rahul Rajeev, MDMedical College of Wisconsin

Milwaukee, WI

George Salti, MDUniversity of Illinois at Chicago and Edward

Cancer Center

Chicago, IL

Paolo Sammartino, MDSapienza University of Rome

Rome, Italy

Armando Sardi, MDMercy Medical Center

Baltimore, MD

Cameron Schlegel, MDVanderbilt University

Nashville, TN

Amy Schulze, MDIndiana University School of Medicine

Indianapolis, IN

Mohammad Shaikh, MDDrexel University College of Medicine

Philadelphia, PA

Simone Sibio, MDUniversity of Rome

Rome, Italy

John Spiliotis, MDMetaxa Cancer Hospital

Piraeus, Greece

Bradley Switzer, MDUniversity of Massachusetts

Worcester, MA

Julie Terhune, MDUniversity of Maryland

Baltimore, MD

Alessandro Testori, MDIstituto Europeo di Oncologia

Milano, Italy

Gregory Tiesi, MDUniversity of Miller School of Medicine

Miami, FL

Kazi Ullah, MDSUNY Stony Brook

Stony Brook, NY

Harold Wanebo, MDRoger Williams Medical Center

Bristol, RI

Matthew Whealon, MDUniversity of California Irvine

Orange, CA

G. Paul Wright, MDUniversity of Pittsburgh Medical Center

Pittsburgh, PA

Yutaka Yonemura, MDKishiwada Tokushukai Hospital

Kyou, Japan

~ 18 ~ ~ 19 ~

Registration Information

Online Registration is accepted until February 12, 2016. After this date, you are only

able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS

conferences.

Visit our online registration site at https://ccehs.upmc.com. Scroll down to the Eleventh

International Symposium on Regional Cancer Therapies section on the web page.

• Click the registration button and enter all of the requested information.

• After registering, an electronic confirmation will be sent to the email address you

provided when you registered.

Registration is not complete until you receive the confirmation email for your

preregistration. If you do not receive this letter within 5­7 days of registration, please

contact Maureen Hewko at (412) 623-5993.

You must bring this confirmation with you to the conference.

Registration Cancellation

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition

cancellations postmarked or date stamped before January 13, 2016 will be completely

refunded. After January 13, 2016, a $35 administrative fee will be assessed. No refunds

will be made after February 1, 2016.

Conference contact for cancellation requests:

Maureen Hewko, MBA

UPMC Cancer Pavilion 413, 5150 Centre Avenue

Pittsburgh, PA 15232

Email: hewkom@upmc.edu • Telephone: (412) 623­5993

Fax: (412) 692­2520

Registration Fees

$350 Physicians and researchers

$250 Nurses and other health care professionals

Registration fee includes:

• Continuing education credit

• Registration and course materials

• Continental breakfast, refreshments and a light lunch

• If interested, workshops on Sunday afternoon.

Meeting Location

The conference will be held at the Sheraton Wild Horse Resort. Conference

reservations are at the sole responsibility of the attendees who may contact the hotel.

If registering for a room at the hotel online, please go to http://www.regionaltherapies.

com and click on conference information.

If you wish to make your reservation by phone, please call 520­796­8278 and mention

that you are with the UPMC group.

The cut­off date for reserving a room at the discounted rate of $234 per night is

January 13, 2016.

Accommodations

Nightly Guest Room Rate: $234 per night

Note: Resorts room rates are subject to additional taxes and resort fees as applicable.

Transportation

If you are flying to the conference, the closest airport to the Sheraton is the Phoenix

International Airport. Please go to www.regionaltherapies.com for information about

transportation from the airport.

For additional information, contact:

Maureen Hewko, MBATelephone: (412) 623­5993Fax: (412) 692­2520Email: hewkom@upmc.eduKoch Center Website: http://www.regionaltherapies.com

Visit the Center for Continuing Education in the Health Sciences Web Site

Our Internet address is: https://ccehs.upmc.com

The UPMC Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs.